Business
Bionomics to Present at Biotech Showcase™ 2024
The Company will provide an update on its leading asset BNC210 and their partnership strategy ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"The Company will provide an update on its leading asset BNC210 and their partnership strategy\nADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the Biotech Showcase™ 2024 taking place January 8-10 in San Francisco, California. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics will be providing an update on the Company’s leading asset, BNC210, a Phase 3 ready α7 nicotinic receptor negative allosteric modulator with the potential to be first- and best-in-class in social anxiety disorder and post-traumatic stress disorder. Presentation informationDay and date: Tuesday, January 9, 2024Time: 4:30 PM PST Location: Hilton San Francisco – Union Square, Yosemite A Company’s management will be available for one-on-one meetings with registered investors and potential partners. In addition, Bionomics will host one-on-one meetings in San Francisco during JP Morgan week. FOR FURTHER INFORMATION PLEASE CONTACT: GeneralRajeev Chandra Company [email protected] RelationsKevin [email protected] RelationsChris [email protected] About Bionomics Limited Bionomics (NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 a...